Cargando…
Local therapy treatment conditions for oligometastatic non-small cell lung cancer
Standard treatments for patients with metastatic non-small cell lung cancer (NSCLC) include palliative chemotherapy and radiotherapy, but with limited survival rates. With the development of improved immunotherapy and targeted therapy, NSCLC prognoses have significantly improved. In recent years, th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773544/ https://www.ncbi.nlm.nih.gov/pubmed/36568167 http://dx.doi.org/10.3389/fonc.2022.1028132 |
_version_ | 1784855214299283456 |
---|---|
author | Zhang, Suli Sun, Qian Cai, Feng Li, Hui Zhou, Yufu |
author_facet | Zhang, Suli Sun, Qian Cai, Feng Li, Hui Zhou, Yufu |
author_sort | Zhang, Suli |
collection | PubMed |
description | Standard treatments for patients with metastatic non-small cell lung cancer (NSCLC) include palliative chemotherapy and radiotherapy, but with limited survival rates. With the development of improved immunotherapy and targeted therapy, NSCLC prognoses have significantly improved. In recent years, the concept of oligometastatic disease has been developed, with randomized trial data showing survival benefits from local ablation therapy (LAT) in patients with oligometastatic NSCLC (OM-NSCLC). LAT includes surgery, stereotactic ablation body radiation therapy, or thermal ablation, and is becoming an important treatment component for OM-NSCLC. However, controversy remains on specific management strategies for the condition. In this review, we gathered current randomized trial data to analyze prognostic factors affecting patient survival, and explored ideal treatment conditions for patients with OM-NSCLC with respect to long-term survival. |
format | Online Article Text |
id | pubmed-9773544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97735442022-12-23 Local therapy treatment conditions for oligometastatic non-small cell lung cancer Zhang, Suli Sun, Qian Cai, Feng Li, Hui Zhou, Yufu Front Oncol Oncology Standard treatments for patients with metastatic non-small cell lung cancer (NSCLC) include palliative chemotherapy and radiotherapy, but with limited survival rates. With the development of improved immunotherapy and targeted therapy, NSCLC prognoses have significantly improved. In recent years, the concept of oligometastatic disease has been developed, with randomized trial data showing survival benefits from local ablation therapy (LAT) in patients with oligometastatic NSCLC (OM-NSCLC). LAT includes surgery, stereotactic ablation body radiation therapy, or thermal ablation, and is becoming an important treatment component for OM-NSCLC. However, controversy remains on specific management strategies for the condition. In this review, we gathered current randomized trial data to analyze prognostic factors affecting patient survival, and explored ideal treatment conditions for patients with OM-NSCLC with respect to long-term survival. Frontiers Media S.A. 2022-12-08 /pmc/articles/PMC9773544/ /pubmed/36568167 http://dx.doi.org/10.3389/fonc.2022.1028132 Text en Copyright © 2022 Zhang, Sun, Cai, Li and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Zhang, Suli Sun, Qian Cai, Feng Li, Hui Zhou, Yufu Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title | Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title_full | Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title_fullStr | Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title_full_unstemmed | Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title_short | Local therapy treatment conditions for oligometastatic non-small cell lung cancer |
title_sort | local therapy treatment conditions for oligometastatic non-small cell lung cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773544/ https://www.ncbi.nlm.nih.gov/pubmed/36568167 http://dx.doi.org/10.3389/fonc.2022.1028132 |
work_keys_str_mv | AT zhangsuli localtherapytreatmentconditionsforoligometastaticnonsmallcelllungcancer AT sunqian localtherapytreatmentconditionsforoligometastaticnonsmallcelllungcancer AT caifeng localtherapytreatmentconditionsforoligometastaticnonsmallcelllungcancer AT lihui localtherapytreatmentconditionsforoligometastaticnonsmallcelllungcancer AT zhouyufu localtherapytreatmentconditionsforoligometastaticnonsmallcelllungcancer |